Claim Missing Document
Check
Articles

Found 4 Documents
Search

Fascin Expression as Prognostic Factor for Survival in Advanced Epithelial Ovarian Carcinoma Vitantri, Fara; Purbadi, Sigit; Siregar, Budiningsih; Sutrisna, Bambang
Indonesian Journal of Obstetrics and Gynecology Volume. 3, No. 4, October 2015
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (333.45 KB) | DOI: 10.32771/inajog.v3i4.58

Abstract

Objective: To evaluate fascin expression as a prognostic factor and its correlation with survival and clinicopathologic factors (degree of differentiation and stage) in epithelial ovarian carcinoma. Methods: This study is prognostic study with historical cohort design. Fascin was analyzed in paraffin block sections of 33 advanced stage ovarian carcinoma patients using immunohistochemistry. Fascin expression was tested for its correlation with overall survival as well as with grade and stage of the cancer. Results: In this study, fascin expression has no correlation with survival. In the period of 17-22 months, samples with high fascin expression had a HR of 1.59 (95% CI=0.38-6.67, p=0.449), but in the period of 17-23 months, both groups had comparable HR. In the period of more than 23 months, samples with high expression of fascin had a better HR of 0.40 (95% CI=0.04-4.38, p=0.449). No significant correlation was found between fascin expression with grade (OR=2.08, 95% CI=0.44-9.84, p=0.442) and stage (OR=2.70, 95% CI=0.39-18.96, p=0.360). Conclusion: In this study, there was no correlation between fascin expression and survival, and also no correlation between fascin, grade and stage. Further study with a larger, more homogenous sample, analyzing confounding factors is needed. [Indones J Obstet Gynecol 2015; 3-4: 222-229] Keywords: advanced stage ovarian carcinoma, fascin, survival
Fascin Expression as Prognostic Factor for Survival in Advanced Epithelial Ovarian Carcinoma Vitantri, Fara; Purbadi, Sigit; Siregar, Budiningsih; Sutrisna, Bambang
Indonesian Journal of Obstetrics and Gynecology Volume. 3, No. 4, October 2015
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (333.45 KB) | DOI: 10.32771/inajog.v3i4.58

Abstract

Objective: To evaluate fascin expression as a prognostic factor and its correlation with survival and clinicopathologic factors (degree of differentiation and stage) in epithelial ovarian carcinoma. Methods: This study is prognostic study with historical cohort design. Fascin was analyzed in paraffin block sections of 33 advanced stage ovarian carcinoma patients using immunohistochemistry. Fascin expression was tested for its correlation with overall survival as well as with grade and stage of the cancer. Results: In this study, fascin expression has no correlation with survival. In the period of 17-22 months, samples with high fascin expression had a HR of 1.59 (95% CI=0.38-6.67, p=0.449), but in the period of 17-23 months, both groups had comparable HR. In the period of more than 23 months, samples with high expression of fascin had a better HR of 0.40 (95% CI=0.04-4.38, p=0.449). No significant correlation was found between fascin expression with grade (OR=2.08, 95% CI=0.44-9.84, p=0.442) and stage (OR=2.70, 95% CI=0.39-18.96, p=0.360). Conclusion: In this study, there was no correlation between fascin expression and survival, and also no correlation between fascin, grade and stage. Further study with a larger, more homogenous sample, analyzing confounding factors is needed. [Indones J Obstet Gynecol 2015; 3-4: 222-229] Keywords: advanced stage ovarian carcinoma, fascin, survival
Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA Ambari, Ediwibowo; Winarto, Hariyono; Sutrisna, Bambang; Siregar, Budiningsih
Indonesian Journal of Obstetrics and Gynecology Volume. 1, No. 3, July 2013
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (101.064 KB) | DOI: 10.32771/inajog.v1i3.357

Abstract

Objectives: To determine the factors that may be used as the prognostic parameter for the therapeutic efficacy of neoadjuvant chemotherapy, which can be used to revising the management of early stage cervical cancer patients with large lesions. Methods: This was a retrospective cohort study. The study was conducted in the Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia. The subjects were 15 cervical cancer stage IB2 and IIA patients with lesions’ size of > 4 cm, who would be treated with neoadjuvant chemotherapy, consisted of cisplatin 50 mg/m2, vincristine 2 mg/m2 and bleomycin 15 mg regiment. The patients’ response would be evaluated after completing 3 series of chemotherapy. Data was retrieved from medical records and cervical biopsy paraffin blocks and examined histopathologically using IHC staining to see expression of caspase-3 with histoscore assessment score. Data was analyzed by univariate, bivariate analysis. Results: Response to PVB neoadjuvant chemotherapy was found in 5 out of 15 patients. None of the clinicopathology variables can be used to predict response to therapy. Expression of caspase-3 as a marker of apoptosis, can not predict the response of the therapy before administrating neoadjuvant chemotherapy either. There is a significant difference between the levels of caspase-3 in epidermoid carcinoma with adenocarcinoma, with p value of 0.02 (RR 6;95% CI 1.69-21.26). Conclusion: Clinicopathologic factors and the expression of caspase-3 before getting chemotherapy neoadjuvant can not predict the succeed of the therapy. [Indones J Obstet Gynecol 2013; 1-3: 156-60] Keywords: caspase -3, clinicopathologic, early-stage cervical cancer lession in large, neoadjuvant chemotherapy response to therapy
PENILAIAN EKSPRESI PROTEIN MDM2 DAN P53 SEBAGAI PREDIKTOR RESPON RADIOTERAPI PADA KANKER SERVIKS Rahayu, Kun Mardiwati; Siregar, Budiningsih; Kurnia, Iin
Bioma Vol. 12 No. 1 (2016): Bioma
Publisher : LPPM Universitas Negeri Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (531.869 KB) | DOI: 10.21009/Bioma12(1).1

Abstract

Cervical cancer is the second most common malignancy in Indonesia, and most of cases were already in advanced stage where radiotherapy is a tratement to given. Apoptosis is one of the markers for survival assessment of therapeutic response. In animal experiments MDM2 expression in various cell types to act as a survival factor by inhibiting the apoptotic function of p53 that is played by apoptosis can lead to malignant transformation and result in resistance to radiotherapy. Therefore, MDM2 is overexpressed due to alleged damage to p53 can also be used to assess the success of radiotherapy. This study aimed to assess the expression of MDM2 and p53 immunohistochemistry in cervical cancer and its relation to radiotherapy response. This study is a retrospective cross-sectional descriptive. The sample consisted of 23 cases of advanced cervical cancer were biopsied, 17 cases with complete response to radiation and 6 cases of partial radiation response. This study showed complete radiotherapy group MDM2 expression was found in 70.59% (12 cases) and p53 expression was found in 94.11% (16 cases), while the expression of MDM2, a partial response was found in 100% (6 cases), while the expression p53 66.67% (4 cases). MDM2 and p53 expression with SPSS 16 chi square test showed no association with response to radiotherapy in cervical cancer.